{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:05:28Z","timestamp":1789236328903,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["B53D23008010006"],"award-info":[{"award-number":["B53D23008010006"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006747","name":"Foundation of the Savings Bank of Verona Vicenza Belluno and Ancona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020349","name":"Italian Foundation for Research on Pancreatic Diseases","doi-asserted-by":"publisher","award":["J38D19000690001"],"award-info":[{"award-number":["J38D19000690001"]}],"id":[{"id":"10.13039\/100020349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["26343"],"award-info":[{"award-number":["26343"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022CMMRWA"],"award-info":[{"award-number":["2022CMMRWA"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.humpath.2025.106014","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:21:31Z","timestamp":1765498891000},"page":"106014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy"],"prefix":"10.1016","volume":"168","author":[{"given":"Carlotta","family":"Franzina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bevere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bersani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mattiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Ceccon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Piccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Malleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita T.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-4908","authenticated-orcid":false,"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2025.106014_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.humpath.2025.106014_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10485","key":"10.1016\/j.humpath.2025.106014_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2025.106014_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.humpath.2025.106014_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"10.1016\/j.humpath.2025.106014_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.humpath.2025.106014_bib7","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3390\/cancers15112955","article-title":"Pancreatic cancer: BRCA targeted therapy and beyond","volume":"15","author":"Keane","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humpath.2025.106014_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","article-title":"KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities","volume":"39","author":"Luchini","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.humpath.2025.106014_bib9","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.humpath.2025.106014_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1136\/gutjnl-2020-320730","article-title":"Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma","volume":"70","author":"Grant","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.humpath.2025.106014_bib12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2024.01.009","article-title":"Fusion genes in pancreatic tumors","volume":"10","author":"Gkountakos","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.humpath.2025.106014_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1369136","article-title":"Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies","volume":"11","author":"Linehan","year":"2024","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10555-025-10243-9","article-title":"Advancements in gene therapies targeting mutant KRAS in cancers","volume":"44","author":"Wang","year":"2025","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.humpath.2025.106014_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14737159.2024.2348676","article-title":"Genomic determinants of biological aggressiveness and poor prognosis of pancreatic cancers: KRAS and beyond","volume":"24","author":"Ciulla","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.humpath.2025.106014_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.humpath.2025.106014_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: a promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.humpath.2025.106014_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102362","article-title":"Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: assessment of a potential clinical biomarker for zolbetuximab therapy","volume":"55","author":"Arseneau","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.humpath.2025.106014_bib20","article-title":"Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2","volume":"611","author":"Tojjari","year":"2024","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.humpath.2025.106014_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","article-title":"Zolbetuximab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.humpath.2025.106014_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark Res"},{"issue":"3","key":"10.1016\/j.humpath.2025.106014_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/PAI.0000000000000175","article-title":"CD71 in gestational pathology: a versatile immunohistochemical marker with new possible applications","volume":"24","author":"Luchini","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"16","key":"10.1016\/j.humpath.2025.106014_bib24","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.3390\/ijms21165794","article-title":"CD117 is a specific marker of intraductal papillary mucinous neoplasms (IPMN) of the pancreas, oncocytic subtype","volume":"21","author":"Mattiolo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.humpath.2025.106014_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-025-04222-2","article-title":"Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring","author":"Luchini","year":"2025","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.humpath.2025.106014_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol"},{"issue":"10389","key":"10.1016\/j.humpath.2025.106014_bib27","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.humpath.2025.106014_bib28","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.humpath.2025.106014_bib29","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.devcel.2025.07.002","article-title":"Emerging insights into lineage plasticity in pancreatic cancer initiation, progression, and therapy resistance","volume":"60","author":"Zhang","year":"2025","journal-title":"Dev Cell"},{"key":"10.1016\/j.humpath.2025.106014_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102479","article-title":"Understanding the heterogeneity of pancreatic ductal adenocarcinoma","volume":"60","author":"Iovanna","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.humpath.2025.106014_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40364-025-00805-y","article-title":"Proteomics in pancreatic cancer","volume":"13","author":"Cai","year":"2025","journal-title":"Biomark Res"},{"key":"10.1016\/j.humpath.2025.106014_bib32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","article-title":"Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination","volume":"27","author":"Ogawa","year":"2024","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","article-title":"Spatial and temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers","volume":"25","author":"Lee","year":"2025","journal-title":"J Gastric Cancer"},{"issue":"4","key":"10.1016\/j.humpath.2025.106014_bib34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10120-025-01609-7","article-title":"Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination","volume":"28","author":"Angerilli","year":"2025","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.humpath.2025.106014_bib35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"W\u00f6ll","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2025.106014_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00428-024-04005-1","article-title":"The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the european society of pathology","volume":"486","author":"Matias-Guiu","year":"2025","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.humpath.2025.106014_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","article-title":"Cancer genome evolutionary trajectories in metastasis","volume":"37","author":"Birkbak","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.humpath.2025.106014_bib39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.humpath.2025.106014_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.molmed.2013.12.005","article-title":"Simplifying the complexity of resistance heterogeneity in metastasis","volume":"20","author":"Lavi","year":"2014","journal-title":"Trends Mol Med"},{"issue":"11","key":"10.1016\/j.humpath.2025.106014_bib41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725003016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725003016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:00:36Z","timestamp":1773900036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725003016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"alternative-id":["S0046817725003016"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106014","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.106014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106014"}}